AHR and thymus atrophy: Supplementary Fig. S5 shows that NAM did not inhibit CYP1A4 induction by the activated AhR in vivo at a dose that protected against thymic atrophy and hepatosteatosis, indicating that AhR activation by TCDD persisted in the presence of NAM in vivo under the conditions shown here.